Journal
BIOMEDICAL MICRODEVICES
Volume 11, Issue 3, Pages 565-570Publisher
SPRINGER
DOI: 10.1007/s10544-008-9263-7
Keywords
Microfluidic device; Infection assay; Antiviral drug; Passive pumping; Quantitative imaging
Funding
- National Institutes of Health [R21 AI071197, K25 CA104162]
- Graduate School of the University of Wisconsin-Madison
- NATIONAL CANCER INSTITUTE [K25CA104162] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI071197, T32AI078985] Funding Source: NIH RePORTER
- NATIONAL LIBRARY OF MEDICINE [T15LM007359] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The plaque assay has long served as the gold standard to measure virus infectivity and test antiviral drugs, but the assay is labor-intensive, lacks sensitivity, uses excessive reagents, and is hard to automate. Recent modification of the assay to exploit flow-enhanced virus spread with quantitative imaging has increased its sensitivity. Here we performed flow-enhanced infection assays in microscale channels, employing passive fluid pumping to inoculate cell monolayers with virus and drive infection spread. Our test of an antiviral drug (5-fluorouracil) against vesicular stomatitis virus infections of BHK cell monolayers yielded a two-fold improvement in sensitivity, relative to the standard assay based on plaque counting. The reduction in scale, simplified fluid handling, image-based quantification, and higher assay sensitivity will enable infection measurements for high-throughput drug screening, sero-conversion testing, and patient-specific diagnosis of viral infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available